Kymera Therapeutics' STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor... | June 14, 2023

Related Keywords

Switzerland ,Watertown ,Massachusetts ,United States ,Lugano ,Ticino ,Boston ,Parco Ciani ,Chris Brinzey ,Bruce Jacobs ,Todd Cooper ,Nello Mainolfi ,Adam Olszewski ,Nasdaq ,Kymera Therapeutics Inc ,Lifespan Cancer Institute ,Corporate Affairs ,Boston Globe ,Exchange Commission ,International Conference On Malignant Lymphoma ,Irakimid Program ,International Conference ,Malignant Lymphoma ,Refractory Lymphomas ,Large Granular Lymphocytic Leukemia ,Marquee Parco ,Rhode Island ,Fierce Biotech ,Boston Business Journal ,Private Securities Litigation Reform Act ,Kymera Therapeutics ,Kymera Therapeutic ,Quarterly Report ,Financial Officer ,Vice President ,